China’s government is slow-rolling approval of its first foreign Covid-19 vaccine out of concern it could undermine confidence in Chinese vaccines, delivering further evidence of the tenacity of vaccine nationalism in the face of a resurgent pandemic.
In addition, the delay buys more time for Chinese drugmakers to introduce their own mRNA vaccines, according to the people and drug industry executives in China.
This, despite the fact that BNTX in in a joint venture for the vaccine with Fosun Pharma (which happens to be RVNC’s Greater China partner for Daxi).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”